Dorsey Wright & Associates Arvinas, Inc. Transaction History
Dorsey Wright & Associates
- $376 Million
- Q2 2024
Shares
3 transactions
Others Institutions Holding ARVN
# of Institutions
224Shares Held
68.6MCall Options Held
166KPut Options Held
31.3K-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$168 Million6.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.67MShares$167 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$156 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.99MShares$99.6 Million0.01% of portfolio
-
Avidity Partners Management LP Dallas, TX2.99MShares$74.6 Million3.91% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $1.33B
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...